·
4 minute read
AI governance in life sciences research means having clear, checkable controls over where your data lives, who can access it, whether it's used to train a vendor's model, and whether every AI-generated claim can be traced back to its source. Data security specifically is one part of that picture: encryption, access controls, and where data physically resides. Governance is the broader discipline that also covers accountability, auditability, and whether an AI system's output can be trusted under regulatory or medical scrutiny.
What "AI Governance" Means for Life Sciences Research
AI governance frameworks exist because "is this AI safe to use" isn't a single yes-or-no question, it's a set of specific, checkable controls. Two frameworks come up most often in 2026: the NIST AI Risk Management Framework, a voluntary framework designed to help organizations build trustworthiness into how AI systems are designed, deployed, and used, and ISO/IEC 42001, the international standard specifically for AI management systems. Organizations are increasingly using the two together rather than picking one.
Regulation is also catching up specifically to healthcare. The EU AI Act treats many healthcare-related AI systems, particularly those used in clinical decision-making, as "high-risk," which generally means mandatory risk management processes, technical documentation, and a formal conformity assessment before deployment. In life sciences specifically, AI governance sits close to patient safety and regulatory scrutiny, not just data privacy in the abstract.
The Real Risks of Using AI With Pharma Data
Three risks come up repeatedly when pharma organizations evaluate an AI vendor:
- Data exposure. Uploading proprietary or patient-related data into a public AI tool can expose sensitive information outside an organization's control. We cover the scale of this risk, including a documented 93% year-over-year increase in enterprise data transferred to AI tools, in why generic AI tools fall short for pharma market research.
- Unaccountable outputs. An AI-generated answer with no traceable source is difficult to defend if a medical, legal, or regulatory reviewer asks where a number came from.
- Data residency and vendor risk. Where data physically resides, and which vendors or subprocessors can access it, has become a sharper compliance question as data sovereignty rules tighten globally, not just a theoretical concern.
What "Evidence Trails" Means, and Why It Matters
An evidence trail is the ability to trace an AI-generated claim back to the specific source, a dataset, a transcript, a deck, that it came from. This matters more in life sciences than in most industries because a research deliverable can inform a launch strategy, a message platform, or a claim that gets reviewed by medical, legal, and regulatory stakeholders before it's used. "The AI said so" isn't a citation. A reviewer needs to be able to check a claim against its source the same way they'd check a colleague's citation in a research memo, not take an AI-generated answer on faith.
A Practical Governance Checklist for Evaluating Any AI Vendor in Life Sciences
Whatever platform or tool a team is evaluating, these are the specific things worth checking, not just asking whether it's "secure":
- Data residency and sovereignty. Where does the data actually live, and does it stay inside your organization's environment or move into a vendor's shared infrastructure?
- Role-based access controls. Can access be restricted by role, so not everyone at an organization can see everything in the system?
- Audit logging. Is there a record of who accessed what, and when, that can be reviewed after the fact?
- Evidence trails. Can every AI-generated answer be traced back to the specific source it came from?
- Identity integration. Does the platform support single sign-on (SSO) through an organization's existing identity provider, rather than a separate login to manage?
- Model training policy. Is your data used to train the vendor's underlying model, or kept separate from model training entirely?
- Key management. Does the vendor support bring-your-own-key (BYOK) deployment, so an organization retains control over its own encryption keys?
How Sagan Agents Approaches Governance
Sagan Agents is built with pharma procurement requirements in mind, not adapted from a consumer product afterward. Client data sovereignty is a design principle, an organization's data stays inside its own environment rather than moving into shared infrastructure. The platform supports SSO integration, role-based access controls, audit logging, and bring-your-own-API-key deployment.
The evidence trail piece runs through the platform by design as well. Every answer from Data Archive Intelligence is sourced and cited back to the original deck, dataset, or transcript it came from, and every workflow runs on a visible, editable roadmap rather than a black box, the mechanics we cover in more depth in Human-in-the-Loop AI: How Sagan Agents Combines AI Speed With Expert Judgment.
See How the Evidence Trail Works on Your Own Data
The clearest way to evaluate an AI platform's governance is to see whether you can trace an actual answer back to its source. Visit the Sagan Agents page to see the full platform, or use the form below to start a conversation about a pilot.
Frequently Asked Questions
